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Increasing rates of invasive candidiasis caused by non-albicans Candida species have been reported world-
wide. Particular concerns have been raised for C. parapsilosis because of reduced in vitro susceptibility to
echinocandins. We identified 212 patients with invasive candidiasis due to non-albicans Candida species (>5
cases per species) in 5 clinical trials of caspofungin monotherapy from the pharmaceutical sponsor’s (Merck
and Co., Inc.) database: 71 cases were caused by C. parapsilosis, 65 by C. tropicalis, 54 by C. glabrata, 10 by C.
krusei, 9 by C. guilliermondii, and 5 by C. lusitaniae. One hundred sixty-seven cases caused by C. albicans were
also identified. Efficacy was assessed at the end of caspofungin therapy. Success (favorable overall response)
required favorable clinical and microbiological responses. The mean APACHE II scores were 16.5 in the
non-albicans group and 15.7 in the C. albicans group. Neutropenia at study entry was more common in the
non-albicans group (12%) than in the C. albicans group (5%). The median duration of caspofungin therapy was
14 days in both groups. The success rates were 77% in both groups and at least 70% for each non-albicans
species: 74% for C. parapsilosis, 71% for C. tropicalis, 85% for C. glabrata, 70% for C. krusei, 89% for C.
guilliermondii, and 100% for C. lusitaniae. The times to negative blood culture were similar for the various
species. The overall mortality rates were 26% in the non-albicans group and 29% in the C. albicans group.
Drug-related serious adverse events and discontinuations due to caspofungin toxicity were uncommon. Al-
though the sample sizes were limited, caspofungin demonstrated favorable efficacy and safety profiles in the
treatment of invasive candidiasis caused by the following non-albicans Candida species: C. parapsilosis, C.
tropicalis, C. glabrata, C. krusei, C. guilliermondii, and C. lusitaniae.
Candida albicans remains the most common pathogen iso-
lated in invasive candidiasis; however, increasing rates of can-
didemia caused by non-albicans Candida species, including C.
tropicalis, C. glabrata, C. parapsilosis, and C. krusei, have been
reported worldwide (16). Non-albicans Candida species ac-
counted for over half the documented cases of candidemia in
several studies from Latin America, Europe, and the United
States (5, 8, 16), and the prevalence of different species varies
substantially from region to region (15, 16). Some of these
species are relatively less susceptible than C. albicans to flu-
conazole. Specifically, C. krusei is inherently resistant and C.
glabrata is routinely less susceptible to fluconazole (7, 17). The
current treatment guidelines for invasive candidiasis issued by
the Infectious Diseases Society of America (IDSA) recom-
mend the use of an echinocandin for infections caused by these
2 species (13). Conversely, in vitro studies have shown that C.
parapsilosis and C. guilliermondii are less susceptible to the
echinocandins than are other Candida species (10, 11, 18), but
the clinical implications of these findings are not clear.
Caspofungin, a member of the echinocandin class, is fungi-
cidal against most Candida species, having demonstrated ac-
tivity against C. albicans, C. tropicalis, C. parapsilosis, C. krusei,
C. glabrata, and C. lusitaniae (1, 3). Caspofungin targets the
fungal cell wall, thereby retaining activity against clinical iso-
lates with documented resistance to either the azoles or the
polyenes (1, 3). Efficacy results from comparative trials have
shown caspofungin to be an effective first-line agent for inva-
sive candidiasis (4, 12). Although the activity for caspofungin
against non-albicans Candida species in these studies was en-
couraging, the extent of efficacy data for each species was often
limited (10 patients per treatment arm). To gain a better
understanding of the efficacy of caspofungin in patients with
non-albicans Candida infection, we performed a retrospective
post hoc review of the current Merck database to identify all
caspofungin-treated patients with invasive candidiasis caused
by non-albicans Candida species. The results are described in
this report relative to results for patients with invasive candi-
diasis caused by C. albicans.
MATERIALS AND METHODS
Patient population. Data from patients receiving caspofungin for the treat-
ment of invasive candidiasis are available from 5 phase II/III clinical studies in
the Merck database (Table 1), 2 of which are comparator-controlled trials (pro-
tocols 014 and 801) (4, 12) and 3 of which are noncomparative studies (protocols
024, 045, and 043) (6, 9, 19). All 5 studies required that patients had proven
invasive candidiasis, as defined by the consensus definitions from the European
Organization for the Research and Treatment of Cancer (EORTC) and the
Mycoses Study Group (MSG) (2). The one notable exception was the allowance
for patients with probable cases of chronic disseminated candidiasis in protocol
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045 (6). Patients received caspofungin as monotherapy in all of these studies;
details of the specific treatment regimens for each study are provided in Table 1.
In general, patients were treated with caspofungin for at least 10 days, and all
antifungal therapy (including subsequent oral fluconazole) was administered for
at least 14 days after the last positive culture of a Candida sp. from blood or
another normally sterile body site. In all studies, careful management of preex-
isting catheters in patients with candidemia was required. Prior to the initiation
of study therapy, all peripheral intravenous or intra-arterial catheters were to be
removed and all central venous catheters were to be removed or changed over a
guide wire. Patients in whom these catheters were not removed are discussed in
the original reports (4, 6, 9, 12, 19).
Efficacy assessment. In all studies, efficacy in all patients who had a confirmed
diagnosis of invasive candidiasis and received at least 1 dose of caspofungin
therapy (referred to as the modified-intention-to-treat population [6, 9, 12, 19] or
the full-analysis-set population [4]) was assessed. In all trials, the primary efficacy
measure was a favorable overall response at the end of caspofungin therapy; this
required a favorable clinical response and a favorable microbiological response.
A favorable clinical response was defined as resolution (complete response)
(4, 6, 12) or improvement (partial response) (9, 19) of all signs, symptoms,
and radiographic abnormalities attributed to Candida infection. A favorable
microbiological response required clearance of Candida from follow-up cul-
tures, including negative results for Candida in blood cultures at the end of
caspofungin therapy in patients with candidemia. For patients with nonblood
candidiasis for whom a follow-up culture could not be obtained, presumptive
eradication (i.e., both clinical and radiographic resolution of infection) was
considered a favorable microbiological response. Relapse assessments varied
by trial; therefore, for this analysis, relapse was assessed at 2 weeks and 4 to
8 weeks after the end of therapy in all patients for whom the proper follow-up
information was available.
Safety assessment. In all studies, adverse events were collected from all pa-
tients for the evaluation of safety. Investigators identified the seriousness, cau-
sality, and action taken on study therapy for all clinical and laboratory adverse
events during the treatment period and for 14 days posttreatment. Adverse
events that were considered by the site investigator to be definitely, probably, or
possibly related to study therapy were classified as drug related.
Statistical considerations. For this post hoc analysis, all patients with a con-
firmed case of invasive candidiasis due to non-albicans Candida species were
identified, provided there were at least 5 cases of infection for that particular
species. The data for patients in each non-albicans group are shown as a separate
column in the tables, followed by a column for the total non-albicans group. Data
for patients with mixed infections caused by 2 or more non-albicans species are
shown separately in each non-albicans group but are only listed once in the total
non-albicans column. All patients with invasive candidiasis due to C. albicans
were also identified and included. Data for patients with mixed infections caused
by C. albicans and a non-albicans Candida species are presented separately under
each species. Efficacy was assessed irrespective of caspofungin dose because prior
studies failed to demonstrate a benefit of higher doses relative to results obtained
with the standard 50-mg daily maintenance dose (4, 6).
The design and sample size of this analysis were not intended to test specific
hypotheses with regard to efficacy or safety. This retrospective post hoc analysis
was predominantly designed as a descriptive comparison of the results across the
different Candida groups. All different analyses and subgroup assessments, in-
cluding tabular displays, were predefined by the authors prior to the compilation
of the data. For the primary efficacy outcome (overall response at the end of
caspofungin therapy), a 95% confidence interval (CI) was calculated as an exact
CI based on the binomial distribution. Assuming a sample size of 50 patients for
each Candida species, the study could rule out observed differences (based on
nonoverlapping 95% CI) between groups of 30 percentage points. For those
groups with at least 10 patients with candidemia, a Kaplan-Meier analysis was
used to assess any differences in the time to negative blood cultures; the log-rank
chi-square statistic was also calculated.
This post hoc analysis focused predominantly on the results from the Merck
database for caspofungin. Of note, the results from a large, prospective study of
caspofungin versus micafungin in invasive candidiasis were not included (14) due
TABLE 1. Description of caspofungin studies for treatment of invasive candidiasis
Protocol Study title Treatment group Caspofungin treatment sample sizea Reference
014 A multicenter, randomized, double-blind,
comparative study to evaluate the safety,
tolerability, and efficacy of caspofungin vs
amphotericin B in the treatment of invasive
candidiasis in adults
Caspofungin 50 mg daily (after
70 mg on day 1) vs
amphotericin B
deoxycholate 0.6–1.0 mg/kg
of body wt daily
109 12
801 A multicenter, randomized, double-blind,
comparative study to evaluate the safety,
tolerability, and efficacy of 2 dosing regimens
of caspofungin in the treatment of invasive
candidiasis in adults
Caspofungin 50 mg daily (after
70 mg on day 1) vs
caspofungin 150 mg daily
197 (102 received the 50-mg dose;
95 received the 150-mg dose)
4
024 A multicenter, open-label, noncomparative,
compassionate-use study to evaluate the safety
and tolerability of caspofungin for the
treatment of invasive candidiasis in adults
refractory to or intolerant of amphotericin B
or amphotericin B lipid formulations
Caspofungin 50 mg daily (after
70 mg on day 1)
15 9
045 A multicenter, open-label, noncomparative study
to estimate the safety, tolerability, and efficacy
of caspofungin in the treatment of adults with
invasive Candida infections (excluding patients
with candidemia as the sole site of infection)
Caspofungin 100 mg daily in
patients with Candida
endocarditis, osteomyelitis,
or septic arthritis;
caspofungin 50 mg daily
(after 70 mg on day 1) in all
other patients
48 (42 received the 50-mg dose; 6
received the 100-mg dose)
6
043 A multicenter, open-label, noncomparative study
to evaluate the safety, tolerability, and efficacy
of caspofungin in children (3 months to 17
years of age) with documented Candida or
Aspergillus infections
Caspofungin 50 mg/m2 daily
(after 70 mg/m2 on day 1
maximum daily dose not to
exceed 70 mg)
37 19
a Sample size is based on modified-intention-to-treat (or full analysis set) population. A total of 27 patients were not included in this post hoc analysis either because
they had an infection caused by a less common non-albicans Candida species or because they did not have available identification of Candida to the species level.
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to the unavailability of the full data set at the Candida species level. A sensitivity
analysis which includes the primary efficacy results from this additional study
combined with the results of the 5 studies from the Merck database (4, 6, 9, 12,
19) has been included in Results.
RESULTS
Patients. In these 5 studies, a total of 212 patients with
invasive candidiasis caused by 6 different non-albicans Candida
TABLE 2. Patient demographics and baseline characteristics
Characteristic
Value no. (%) of patients or as indicated for group
C. glabrata C. guilliermondii C. krusei C. lusitaniae C. parapsilosis C. tropicalis
Total
non-albicans
speciesa
C. albicans
Total no. of patients 54 9 10 5 71 65 212 167
Gender
Male 21 (39) 4 (44) 5 (50) 3 (60) 50 (70) 33 (51) 115 (54) 88 (53)
Female 33 (61) 5 (56) 5 (50) 2 (40) 21 (30) 32 (49) 97 (46) 79 (47)
Race
Caucasian 41 (76) 7 (78) 7 (70) 2 (40) 45 (63) 40 (62) 141 (67) 116 (69)
Black 4 (7) 2 (22) 1 (10) 1 (20) 7 (10) 10 (15) 24 (11) 15 (9)
Asian 2 (4) 10 (14) 11 (17) 23 (11) 9 (5)
Hispanic 6 (11) 2 (20) 1 (20) 9 (13) 3 (5) 21 (10) 20 (12)
Other 1 (2) 1 (20) 1 (1) 3 (1) 7 (4)
Age (yr)
Mean 57.8 42.1 45.4 34.7 47.7 51.8 50.8 52.7
Median 61.0 35.0 46.0 3.0 49.0 54.0 54.5 57.0
Range 3–90 7–67 6–73 2–90 1–87 2–90 1–90 1–88
APACHE II scoreb
20 36 (67) 5 (56) 8 (80) 46 (65) 42 (65) 135 (64) 117 (70)
20 9 (17) 2 (22) 1 (10) 2 (40) 16 (23) 17 (26) 47 (22) 31 (19)
Mean 16.2 16.9 12.2 30.5 15.8 17.4 16.5 15.7
Median 15.0 17.0 12.0 30.5 15.0 17.0 16.0 15.0
Range 8–34 12–21 0–21 29–32 2–37 2–39 0–39 2–38
Neutropenia status at
study entryc
ANC, 500 cells/l 51 (94) 7 (78) 7 (70) 5 (100) 68 (96) 51 (78) 187 (88) 159 (95)
ANC, 500 cells/l 3 (6) 2 (22) 3 (30) 3 (4) 14 (22) 25 (12) 8 (5)
Reason for study entry
Primary therapy 47 (87) 9 (100) 8 (80) 5 (100) 69 (97) 62 (95) 199 (94) 151 (90)
Salvage therapy 7 (13) 2 (20) 2 (3) 3 (5) 13 (6) 16 (10)
Most common risk
factord
Active malignancy 12 (22) 6 (67) 5 (50) 2 (40) 18 (25) 23 (35) 65 (30) 39 (23)
Broad spectrum
antibiotics
37 (69) 7 (78) 9 (90) 5 (100) 63 (89) 50 (77) 169 (79) 125 (75)
Major surgery 28 (52) 1 (11) 2 (20) 2 (40) 35 (49) 22 (34) 88 (41) 85 (51)
Total parenteral
nutrition
29 (54) 1 (11) 1 (10) 2 (40) 31 (44) 17 (26) 81 (38) 66 (40)
Site of Candida infection
Blood 37 (69) 9 (100) 7 (70) 5 (100) 69 (97) 59 (91) 185 (87) 118 (71)
Intra-abdominal
abscess
11 (20) 2 (20) 1 (2) 13 (6) 16 (10)
Bone/joint space 1 (2) 1 (10) 1 (1) 3 (1) 5 (3)
Peritoneal fluid 2 (4) 2 (3) 4 (2) 14 (8)
Pleural fluid 1 (2) 1 (1) 1 (2) 3 (1) 1 (1)
Othere 2 (4) 2 (3) 4 (2) 13 (8)
a Data for patients with mixed infections are displayed under each applicable pathogen but only once in the total non-albicans group.
b APACHE II scores were not collected in protocols 024 and 043.
c ANC, absolute neutrophil count.
d Patients with more than 1 risk factor are counted in each of the different categories.
e Other sites of infection among the non-albicans group included 2 patients with pyelonephritis (both with C. glabrata) and 2 patients with nonabdominal abscesses
(both with C. tropicalis). Other sites of infection among the C. albicans group included 8 patients with other abscesses, 2 patients with Candida pneumonia, and 3 patients
with pancreatic involvement.
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species (Table 2), including C. glabrata (n  54), C. guillier-
mondii (n  9), C. krusei (n  10), C. lusitaniae (n  5), C.
parapsilosis (n 71), and C. tropicalis (n 65), were identified.
Two patients had mixed infections caused by 2 non-albicans
Candida species, including one patient with C. guilliermondii
and C. parapsilosis infection and another patient with C. gla-
brata and C. krusei infection. Data are also available for 167
patients with invasive candidiasis caused by C. albicans who
were in these 5 studies. The distribution of patient demograph-
ics was generally similar in the combined non-albicans group
and the C. albicans group. The median APACHE II score was
between 15 and 17 for all species except for C. krusei and C.
lusitaniae. APACHE II scores at study entry were higher in
patients with C. lusitaniae infection than in any other group,
but the number of patients with this species was limited. Pa-
tients with C. guilliermondii, C. krusei, or C. tropicalis infection
had higher rates (each 20%) of neutropenia than the other
groups at study entry. Across the combined non-albicans group
and the C. albicans group, the most common risk factors were
broad spectrum antibiotics, followed by major surgery, total
parenteral nutrition, and active malignancy. Candidemia was
the most common site of infection in all groups, ranging from
69 to 100% of patients. Approximately 20% of patients with C.
glabrata or C. krusei infection had intra-abdominal abscess.
Caspofungin was predominantly dosed at 50 mg daily (fol-
lowing a 70-mg loading dose on day 1) in adults or 50 mg/m2
daily (following a 70-mg/m2 loading dose on day 1), with the
maximum not to exceed 70 mg, in pediatric patients; these
regimens were used in 74% of patients with non-albicans Can-
dida infection and in 72% of those with C. albicans infection.
The remaining patients (all adults) received caspofungin at 100
or 150 mg daily (Table 3). The duration of caspofungin therapy
ranged from 1 to 57 days (median, 14 days) and was generally
similar across the different groups (Table 3).
Efficacy. At the end of caspofungin therapy, a favorable
overall response was achieved in 70% to 100% of patients with
non-albicans infections. Notably, a response rate of 74% (46/
65) was seen in patients with infections caused by C. parapsi-
losis (Table 4). For comparison, the success rate was 77% in
the 167 patients with C. albicans infection from these same 5
studies. Response rates by site of Candida infection or by
reason for study entry (primary or salvage treatment) were
generally similar across the different species. Among neutro-
penic patients, the response rate was somewhat lower in pa-
tients with C. tropicalis (6/14, 43%) or C. albicans (2/8, 25%)
infection than in patients with the other non-albicans Candida
species.
Reasons for unfavorable responses were generally similar
across the Candida species. One notable finding was that a
slightly higher proportion of patients with C. parapsilosis (12/
70, 17%) had persistently positive cultures listed as the primary
reason for failure at the end of study therapy than was the case
for groups with other Candida spp., among which the propor-
tions of patients with persistently positive cultures were 10%
(1/10) with C. krusei, 8% (14/166) with C. albicans, 5% (3/65)
with C. tropicalis, and 2% (1/54) with C. glabrata. However, this
finding was not confirmed when an analysis evaluating the time
to a negative blood culture was performed in patients with
candidemia. In those groups with at least 10 patients with
candidemia, the median times to achieving a negative blood
culture for C. glabrata, C. parapsilosis, C. tropicalis, C. krusei,
and C. albicans were 2.0, 2.5, 3.0, 3.5, and 5.0 days, respectively
(Fig. 1). The log-rank chi-square statistic was not significant
(P 0.522), suggesting that there was no difference among the
Candida species with respect to time to achieve a negative
blood culture. Among these same groups, an assessment was
also made to determine the proportion of patients with persis-
tent candidemia at 72 h after the beginning of caspofungin
therapy. The proportions were similar across the 4 non-albi-
cans groups and the C. albicans group.
At 2 weeks after the end of caspofungin therapy, relapse of
invasive candidiasis occurred in 3% of patients in the com-
bined non-albicans group and 4% of patients in the C. albicans
group. The relapse rates at 4 to 8 weeks after the end of
therapy were 6% and 8%, respectively (Table 4).
Mortality from all causes was 26% across the combined
non-albicans group and 29% in the C. albicans group (Table 4).
Mortality was slightly higher among patients with C. tropicalis
(38%) or C. krusei (40%) infection. The mortality rate in pa-
tients with C. parapsilosis (20%) was lower than the mean
overall mortality but was comparable to the rate in patients
with C. glabrata infection (20%) and higher than that in pa-
tients with C. guilliermondii infection (11%).
A sensitivity analysis was performed which included the pri-
mary efficacy results from the caspofungin treatment group in
the caspofungin versus micafungin study of invasive candidiasis
(14). With the inclusion of this data, the observed overall
response rates for caspofungin against each of the 5 most
common Candida species remain above 70% (Table 5).
Safety. Serious drug-related adverse events occurred in 2
patients (1%) with non-albicans Candida infection (one with C.
glabrata and one with C. tropicalis infection) and 2 patients
(1%) with C. albicans infection. Caspofungin therapy was dis-
continued due to a drug-related adverse event in 4 patients
(2%) with non-albicans Candida infection (2 with C. tropicalis,
one with C. glabrata, and one with C. parapsilosis) and 3 pa-
tients (2%) with C. albicans infection. All serious drug-related
adverse events and drug-related adverse events leading to dis-
continuation of caspofungin were distinct terms; no specific
adverse event occurred in more than 1 patient.
TABLE 3. Caspofungin dosage and duration of therapy
Pathogen (total no. of
patients in group)
No. (%) of patients
receiving caspofungin
daily dosage of:
Duration of therapy
(days)
50 mga 100 mg Mean Median Range
C. glabrata (54) 44 (81) 10 (19) 16.8 14 6–37
C. guilliermondii (9) 8 (89) 1 (11) 12.9 14 3–28
C. krusei (10) 8 (80) 2 (20) 13.7 12 4–35
C. lusitaniae (5) 4 (80) 1 (20) 14.4 16 3–21
C. parapsilosis (71) 49 (69) 22 (31) 14.8 14 2–48
C. tropicalis (65) 46 (71) 19 (29) 13.4 12 1–57
Non-albicans
species (212)b
157 (74) 55 (26) 14.6 14 1–57
C. albicans (167) 121 (72) 46 (28) 15.3 14 1–85
a Pediatric patients received 50 mg/m2 daily following a 70-mg/m2 loading dose
on day 1 (maximum not to exceed 70 mg/day).
b Data for patients with mixed infections are displayed for each applicable
pathogen but only once in the total non-albicans group.
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DISCUSSION
Candida species other than C. albicans account for 40 to
55% of yeast bloodstream infections worldwide (16). Notably,
C. glabrata, C. parapsilosis, and C. tropicalis are the most com-
monly recovered non-albicans species overall, accounting for
15%, 15%, and 9%, respectively, of all candidemia cases in the
SENTRY antimicrobial surveillance program (17). Although it
is encountered less frequently, C. krusei is also an important
non-albicans species due to its inherent resistance to flucon-
azole (7, 17). To better understand the efficacy of caspofungin
against non-albicans Candida species, we utilized data from 5
clinical studies to examine patient outcomes in 212 cases of
invasive candidiasis caused by these 4 species (C. glabrata, C.
parapsilosis, C. tropicalis, and C. krusei) and 2 other less com-
mon species (C. guilliermondii and C. lusitaniae).
In these 212 patients, success rates were generally high
across the various non-albicans species, with a minimum suc-
cess rate of 70% for each of these species. For comparison, a
success rate of 77% was seen in the 167 patients with C.
albicans infection from these same 5 studies. Even in specific
patient subgroups, success was seen for the various non-albi-
cans groups. Among patients with a non-albicans Candida in-
fection, favorable responses were seen in patients with under-
lying neutropenia, patients with less common forms of invasive
candidiasis, and patients receiving caspofungin as a second-line
(salvage) treatment option.
Particular attention has been focused on those non-albicans
species which have been reported to be less susceptible to the
echinocandins, namely, C. parapsilosis and C. guilliermondii
(10, 11, 18). Recent IDSA guidelines recommend that patients
with an infection caused by C. parapsilosis should be treated
with fluconazole, although the continuation of an echinocandin
is reasonable for those patients showing clinical and microbi-
ological improvement following initial treatment with an echi-
nocandin (13). In this analysis, the success rate among patients
with a C. parapsilosis infection was 74%, and the time to clear-
ance of infection from the bloodstream and the rate of relapse
in this group were comparable to those seen with other Can-
dida species. Additionally, the success rate was 89% in patients
with a C. guilliermondii infection. Even though the baseline
APACHE II scores in patients with C. parapsilosis or C. guil-
liermondii were comparable to those seen with other species,
the overall mortality with these 2 species was only 19%. This
finding may attest to the less virulent nature of these 2 patho-
gens.
FIG. 1. Kaplan-Meier curves of the proportions of patients with positive blood cultures by day of study therapy and by Candida species (N,
number of patients included at the specified time point). For those species infecting at least 10 patients, all patients with candidemia who had a
positive blood culture at baseline were included. One patient had positive blood cultures for C. glabrata and C. tropicalis at baseline; time to C.
glabrata eradication and time to C. tropicalis eradication are displayed separately for this patient.
TABLE 5. Patient efficacy outcomes, including results from the
caspofungin treatment group in the caspofungin versus
micafungin study, for invasive candidiasis
Pathogen
No. of patients with a favorable
response/no. of patients in
subgroup (%)
95% CI
C. glabrata 68/87 (78) 68, 86
C. krusei 10/14 (71) 42, 92
C. parapsilosis 79/112 (71) 61, 79
C. tropicalis 70/97 (72) 62, 81
C. albicans 188/249 (76) 70, 81
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The observed safety profile of caspofungin in patients with
non-albicans Candida infection was generally similar to that in
patients with C. albicans infection. In both groups, serious
drug-related adverse events and discontinuations due to drug-
related adverse events were uncommon. About 25% of the
patients in this analysis received caspofungin at higher than
approved doses. Previous studies have shown that the safety
profile of caspofungin at these higher doses is similar to that
observed for the standard regimen (50 mg daily after 70 mg on
day 1) (4, 6).
This analysis has several notable limitations. First, efficacy
was assessed irrespective of different doses of caspofungin.
Although this approach was justified by the knowledge that the
overall efficacy of caspofungin across different doses in adults
(50 to 150 mg daily) (4, 6) and pediatric patients (50 mg/m2
daily) (19) was comparable, differences within patient sub-
groups may have been influenced by the chosen dose. Second,
these 5 studies were conducted at different centers and over
different time periods. The efficacy against different species
may have been influenced by site-specific differences at these
different centers over time. Third, this analysis was conducted
as a post hoc analysis. The combination of the data across these
5 studies was not predefined in any of the protocols or statis-
tical analysis plans for these different studies. A final limitation
of the current analysis is that it does not include all clinical
studies of caspofungin in the treatment of invasive candidiasis
conducted to date. Particularly, the results from a large, pro-
spective study of caspofungin versus micafungin in invasive
candidiasis were excluded from all analyses because the results
of the baseline characteristics, demographics, duration of ther-
apy, and safety were summarized at the treatment group level
and not the species level. A major strength of our analysis is
that all the detailed data across these different indices have
been included at the Candida species level, thereby allowing
for a more accurate assessment of the efficacy of caspofungin
for each of the different Candida species without bias to po-
tential underlying factors. Nevertheless, a sensitivity analysis
was also performed with the inclusion of the caspofungin pri-
mary efficacy data from the caspofungin versus micafungin
study (14). The inclusion of this additional study does not
significantly change the findings seen in our analysis.
Although the present study is still underpowered to defi-
nitely solve concerns that have arisen from in vitro data, the
results of this study suggest that caspofungin provides thera-
peutic efficacy in patients with invasive candidiasis caused by C.
parapsilosis, C. tropicalis, C. glabrata, C. krusei, C. guilliermon-
dii, and C. lusitaniae. Although the number of cases was lim-
ited, the observed efficacy of caspofungin in patients with C.
parapsilosis infection remained over 70%. Caspofungin also
manifested a favorable safety profile in patients with non-
albicans Candida infection, with very few serious drug-related
adverse events or discontinuations because of toxicity. It is
important to remember that no single randomized clinical trial
with sufficient power to evaluate possible differences in the
efficacy of antifungal drugs to treat non-albicans Candida spe-
cies has been conducted, and we expect that such a study is not
likely to be performed in the near future. In this scenario, our
study adds relevant data to the field and provides information
suggesting that caspofungin may be used as first-line therapy
for invasive candidiasis caused by non-albicans Candida spe-
cies, even in regions where C. parapsilosis is highly prevalent.
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